



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Mark Hackett**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 22-G-001**

You asked:

1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

2) Of these five, how many of each received the following products:

- **Adalimumab (Humira)**
- **Adalimumab Biosimilar**
- **Etanercept (Enbrel)**
- **Etanercept Biosimilar**
- **Infliximab (Remicade)**
- **Infliximab biosimilar**
- **Golimumab (Simponi)**
- **Tofacitinib (Xeljanz)**
- **Ustekinumab (Stelara)**
- **Vedolizumab (Entyvio)**
- **Filgotinib (Jyseleca)**
- **Abatacept (Orencia)**
- **Baricitinib (Olumiant)**
- **Certolizumab Pegol (Cimzia)**
- **Rituximab (MabThera)**
- **Rituximab Biosimilar**
- **Tocilizumab (RoActemra)**



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

- **Sarilumab (Kevzara)**
- **Apremilast (Otezla)**
- **Secukinumab (Cosentyx)**
- **Isekizumab (Taltz)**
- **Guselkumab (Tremfya)**
- **Brodalumab (Kyntheum)**
- **Risankizumab (Skyrizi)**
- **Tildrakizumab (Ilumetri)**
- **Upadacitinib (Rinvoq)**
- **Bimekizumab (Bimzelx)**

3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- **AxSPA**
- **PsA**
- **PsO**

Our response:

Patients suffering with Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis or hidradenitis suppurativa would be treated via our Outpatients department. Patients treated as an Outpatient do not have their treatments or procedures "coded" and logged on our centralised system in the way that inpatients do. To obtain this information would involve a manual trawl and search of patient records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

